Lantern Pharma is trading at $1.25, down 10.07%, amid biotech-sector weakness.
- No new company-specific announcement was identified for September 24, 2026.
- XBI was down 2.04% during regular trading. Earlier reporting linked biotechnology losses to higher Treasury yields, inflation concerns, and firmer oil.
- Broader indexes were also lower, but the sector decline was substantially sharper than the major-market moves.